-
EP4608862
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4608862
| EP4608862 - COMPOSITIONS OF ANTI-INTERLEUKIN 12/INTERLEUKIN 23 ANTIBODY [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 01.08.2025 Database last updated on 11.04.2026 | |
| Former | The international publication has been made Status updated on 04.05.2024 | ||
| Former | unknown Status updated on 06.12.2023 | Most recent event Tooltip | 09.01.2026 | Change: Validation states | published on 11.02.2026 [2026/07] | 09.01.2026 | Change - extension states | published on 11.02.2026 [2026/07] | Applicant(s) | For all designated states Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US | [2025/36] | Inventor(s) | 01 /
BRIDGEWATER, Juma Thousand Oaks, California 91320-1799 / US | 02 /
PRABHU, Siddharth Thousand Oaks, California 91320-1799 / US | 03 /
TOKUDA, Joshua Thousand Oaks, California 91320-1799 / US | 04 /
XIANG, Dong Thousand Oaks, California 91320-1799 / US | 05 /
JOUBERT, Marisa Thousand Oaks, California 91320-1799 / US | 06 /
LIU, Qian Thousand Oaks, California 91320-1799 / US | 07 /
POLOZOVA, Alla Thousand Oaks, California 91320-1799 / US | 08 /
ELBARADEI, Ahmed Thousand Oaks, California 91320-1799 / US | [2025/36] | Representative(s) | Grünecker Patent- und Rechtsanwälte PartG mbB Leopoldstraße 4 80802 München / DE | [2025/36] | Application number, filing date | 23814019.8 | 27.10.2023 | [2025/36] | WO2023US78032 | Priority number, date | US202263381459P | 28.10.2022 Original published format: US 202263381459 P | US202363583438P | 18.09.2023 Original published format: US 202363583438 P | US202363591990P | 20.10.2023 Original published format: US 202363591990 P | [2025/36] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2024092203 | Date: | 02.05.2024 | Language: | EN | [2024/18] | Type: | A1 Application with search report | No.: | EP4608862 | Date: | 03.09.2025 | Language: | EN | The application published by WIPO in one of the EPO official languages on 02.05.2024 takes the place of the publication of the European patent application. | [2025/36] | Search report(s) | International search report - published on: | EP | 02.05.2024 | Classification | IPC: | C07K16/24 | [2025/36] | CPC: |
C07K16/244 (EP);
G01N33/6848 (EP);
G01N33/6869 (EP);
C07K2317/41 (EP);
C07K2317/565 (EP);
C07K2317/567 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2025/36] | Title | German: | ZUSAMMENSETZUNGEN VON ANTI-INTERLEUKIN 12/INTERLEUKIN 23-ANTIKÖRPERN | [2025/36] | English: | COMPOSITIONS OF ANTI-INTERLEUKIN 12/INTERLEUKIN 23 ANTIBODY | [2025/36] | French: | COMPOSITIONS D'ANTICORPS ANTI-INTERLEUKINE 12/INTERLEUKINE 23 | [2025/36] | Entry into regional phase | 13.05.2025 | National basic fee paid | 13.05.2025 | Designation fee(s) paid | 13.05.2025 | Examination fee paid | Examination procedure | 13.05.2025 | Examination requested [2025/36] | 13.05.2025 | Date on which the examining division has become responsible | 28.11.2025 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 22.10.2025 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [IY] US2020291107 (BARNTHOUSE KRISTOPHER et al.) | [IY] CN114395041 (GANLI PHARMACY CO LTD et al.) | [IY] WO2020142275 (MOMENTA PHARMACEUTICALS INC et al.) | [Y] US2019321752 (RANDOLPH PAUL et al.) | by applicant | WO2022132982 | US2021063641 | COBB, BA: "The history of IgG glycosylation and where we are now", GLYCOBIOLOGY, vol. 30, no. 4, 2020, pages 202 - 213 | IMMUNOL LETT, vol. 111, 2007, pages 66 - 8 | BECK ALIU H: "Macro- and micro-heterogeneity of natural and recombinant IgG antibodies", ANTIBODIES, vol. 8, no. 1, 2019, pages 18 | SHAH B ET AL.: "J Pharm Sci", 2022, PRESS, article "Heavy-chain C-terminal amidation in therapeutic IgG does not pose a safety concern" | TSUBAKI M ET AL.: "C-terminal modification of monoclonal antibody drugs: amidated species as a general product-related substance", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 52, 2013, pages 139 - 47, XP055120412, DOI: 10.1016/j.ijbiomac.2012.09.016 DOI: http://dx.doi.org/10.1016/j.ijbiomac.2012.09.016 | "REMINGTON'S PHARMACEUTICAL SCIENCES", 1990, MACK PUBLISHING COMPANY |